|
|
Post by dreamboatcruise on Sept 6, 2017 12:47:19 GMT -5
Interesting... the poster doesn't seem to support some of their other claims.
|
|
|
|
Post by mango on Sept 6, 2017 12:48:28 GMT -5
|
|
|
|
Post by mango on Sept 6, 2017 13:08:52 GMT -5
That was from 2008 so I don't know if there is a newer one or not.
But, "With a lesser effect on the surge of plasma insulin" equates to not mimicking the first phase insulin response which means it doesn't restore and maintain glucose homeostasis.
|
|
|
|
Post by peppy on Sept 6, 2017 13:16:53 GMT -5
oramed insulin takes two and 1/2 hours to work?
www.oramed.com/wp-content/uploads/2015/01/ADA-2008-Poster.pdf
notice the sell is 8 units of insulin rather than 230 units of insulin.
June 6-10, 2008
Conclusions
Pharmacokiinetiics ((PK)) and Pharmacodynamiics ((PD)) off
Orall IInsulliin iin Heallthy Subjjects
Miriam Kidron, Ph.D, Itamar Raz, M.D. MichaWolfensberger, *Herve Schwob Ph.D *Christian Schruefer
Diabetes Unit, Hadassah University Hospital, and Oramed Pharmaceuticals, Jerusalem Israel * Swiss Caps, Kirchberg Switzerland
Eight healthy male volunteers (mean age
25 years, BMI 20.1-17.7 kg/m²)
participated in this 4-period, cross-over
study. During each visit, separated by a 72
to 96 hours washout period, and after an
overnight fast, subjects were administered
an oral insulin capsule containing 8 mg of
insulin combined with varying doses of
Oramed’s enhancing agents
(formulations).
The pharamcokinetic profile of each
insulin formulation and its metabolic
effects on glucose, insulin and c-peptide
were assessed over a five hour period
Conclusion: The results of this study in healthy volunteers
were positive and showed that insulin
administered by Oramed’s capsules;
A) Is absorbed and is biologically active.
B) It exhibits unique Pk and PD effects
characterized by the delayed onset of action and a
prolonged metabolic effect as compared with
other oral or inhaled formulations currently
under study. These encouraging results justify
further clinical studies to assess the clinical
potential of this formulation.
Conceivably, the potential clinical utility of the
current prototypic formulation maybe in: playing
a role in IGT and early stage T2DM where it will
serves to supplement endogenous insulin, and
thus reduce the burden of “overdrive” on islet
cells, as suggested by the observed consistent
reduction in c-peptide in this study.
|
|
|
|
Post by mango on Sept 6, 2017 13:29:52 GMT -5
oramed insulin takes two and 1/2 hours to work?
www.oramed.com/wp-content/uploads/2015/01/ADA-2008-Poster.pdf
notice the sell is 8 units of insulin rather than 230 units of insulin.
June 6-10, 2008
Conclusions
Pharmacokiinetiics ((PK)) and Pharmacodynamiics ((PD)) off
Orall IInsulliin iin Heallthy Subjjects
Miriam Kidron, Ph.D, Itamar Raz, M.D. MichaWolfensberger, *Herve Schwob Ph.D *Christian Schruefer
Diabetes Unit, Hadassah University Hospital, and Oramed Pharmaceuticals, Jerusalem Israel * Swiss Caps, Kirchberg Switzerland
Eight healthy male volunteers (mean age
25 years, BMI 20.1-17.7 kg/m²)
participated in this 4-period, cross-over
study. During each visit, separated by a 72
to 96 hours washout period, and after an
overnight fast, subjects were administered
an oral insulin capsule containing 8 mg of
insulin combined with varying doses of
Oramed’s enhancing agents
(formulations).
The pharamcokinetic profile of each
insulin formulation and its metabolic
effects on glucose, insulin and c-peptide
were assessed over a five hour period
Conclusion: The results of this study in healthy volunteers
were positive and showed that insulin
administered by Oramed’s capsules;
A) Is absorbed and is biologically active.
B) It exhibits unique Pk and PD effects
characterized by the delayed onset of action and a
prolonged metabolic effect as compared with
other oral or inhaled formulations currently
under study. These encouraging results justify
further clinical studies to assess the clinical
potential of this formulation.
Conceivably, the potential clinical utility of the
current prototypic formulation maybe in: playing
a role in IGT and early stage T2DM where it will
serves to supplement endogenous insulin, and
thus reduce the burden of “overdrive” on islet
cells, as suggested by the observed consistent
reduction in c-peptide in this study.
Looks like a load of BS to me. |
|
|
|
Post by brentie on Sept 6, 2017 14:53:15 GMT -5
|
|
|
|
Post by sayhey24 on Sept 6, 2017 15:07:17 GMT -5
Mango - thanks, I went right to the poster before I saw your next post. Yes, I would agree with BS. When they say unique, they ain't kidding. My first question is what is their rate of hypoglycemia? I don't see it mentioned in the poster. This looks potentially very dangerous.
|
|
|
|
Post by liane on Sept 6, 2017 15:08:46 GMT -5
Thanks brentie. This is what I inherently knew about ORMP, but didn't want to bother to find again. |
|
|
|
Post by ilovekauai on Sept 6, 2017 15:13:35 GMT -5
No one can touch Afrezza effectiveness across the board and that's a fact. Out time is coming. Aloha.
|
|
|
|
Post by sportsrancho on Sept 6, 2017 15:15:35 GMT -5
What does all this have to do with MNKD? Are we worried... 30 pills a day!
|
|
